{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:49:09Z","timestamp":1790225349492,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1097\/inf.0000000000001241","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T09:54:00Z","timestamp":1464861240000},"page":"1011-1020","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Immunogenicity of M-M-RII (Combination Measles\u2013Mumps\u2013Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009"],"prefix":"10.1097","volume":"35","author":[{"given":"Barbara J.","family":"Kuter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwy","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210202","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1542\/peds.76.4.524","article-title":"Health impact of measles vaccination in the United States.","volume":"76","author":"Bloch","year":"1985","journal-title":"Pediatrics"},{"key":"R2-18-20210202","first-page":"107","article-title":"Epidemiology of rubella.","volume":"118","author":"Witte","year":"1969","journal-title":"Am J Dis Child"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1016\/j.vaccine.2009.06.109","article-title":"Mumps resurgences in the United States: a historical perspective on unexpected elements.","volume":"27","author":"Barskey","year":"2009","journal-title":"Vaccine"},{"key":"R6-18-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1542\/peds.68.1.18","article-title":"Clinical and serologic evaluation of measles, mumps, and rubella (HPV-77:DE-5 and RA 27\/3) virus vaccines, singly and in combination.","volume":"68","author":"Lerman","year":"1981","journal-title":"Pediatrics"},{"key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3181\/00379727-165-40931","article-title":"Clinical and laboratory studies of live attenuated RA 27\/3 and HPV 77-DE rubella virus vaccines.","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"R8-18-20210202","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199411243312101","article-title":"The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.","volume":"331","author":"Peltola","year":"1994","journal-title":"N Engl J Med"},{"key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/bmj.295.6608.1264","article-title":"Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.","volume":"295","author":"B\u00f6ttiger","year":"1987","journal-title":"Br Med J (Clin Res Ed"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1473-3099(08)70282-2","article-title":"Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme.","volume":"8","author":"Peltola","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R12-18-20210202","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/377696","article-title":"Summary and conclusions: measles elimination meeting, 16\u201317 March 2000.","volume":"189","author":"Katz","year":"2004","journal-title":"J Infect Dis"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"S5123","DOI":"10.1086\/505943","article-title":"The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement","volume":"43","author":"Reef","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R14-18-20210202","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3181\/00379727-165-40979","article-title":"Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27\/3 rubella virus.","volume":"165","author":"Weibel","year":"1980","journal-title":"Proc Soc Exp Biol Med"},{"key":"R15-18-20210202","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.vaccine.2015.03.017","article-title":"M-M-R(\u00ae)II manufactured using recombinant human albumin (rHA) and M-M-R(\u00ae)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.","volume":"33","author":"Wiedmann","year":"2015","journal-title":"Vaccine"},{"key":"R16-18-20210202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/infdis\/149.5.810","article-title":"Epidemiological standardization of a test for susceptibility to mumps.","volume":"149","author":"Shehab","year":"1984","journal-title":"J Infect Dis"},{"key":"R17-18-20210202","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/00006454-199608000-00010","article-title":"Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.","volume":"15","author":"Johnson","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/oxfordjournals.aje.a116479","article-title":"Confounding in studies of adverse reactions to vaccines.","volume":"136","author":"Fine","year":"1992","journal-title":"Am J Epidemiol"},{"key":"R19-18-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(05)78423-3","article-title":"Vaccine adverse events: causal or coincidental?","volume":"351","author":"Chen","year":"1998","journal-title":"Lancet"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1542\/peds.106.5.e62","article-title":"Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination.","volume":"106","author":"Virtanen","year":"2000","journal-title":"Pediatrics"},{"key":"R21-18-20210202","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1542\/peds.2006-0678","article-title":"Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.","volume":"118","author":"LeBaron","year":"2006","journal-title":"Pediatrics"},{"key":"R22-18-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(86)91044-5","article-title":"Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins.","volume":"1","author":"Peltola","year":"1986","journal-title":"Lancet"},{"key":"R23-18-20210202","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1542\/peds.100.5.767","article-title":"MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team.","volume":"100","author":"Davis","year":"1997","journal-title":"Pediatrics"},{"key":"R24-18-20210202","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.292.3.351","article-title":"MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.","volume":"292","author":"Vestergaard","year":"2004","journal-title":"JAMA"},{"key":"R26-18-20210202","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMoa003077","article-title":"The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.","volume":"345","author":"Barlow","year":"2001","journal-title":"N Engl J Med"},{"key":"R27-18-20210202","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(95)90471-9","article-title":"A new method for active surveillance of adverse events from diphtheria\/tetanus\/pertussis and measles\/mumps\/rubella vaccines.","volume":"345","author":"Farrington","year":"1995","journal-title":"Lancet"},{"key":"R28-18-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1542\/peds.88.5.881","article-title":"Risk of seizures after measles-mumps-rubella immunization.","volume":"88","author":"Griffin","year":"1991","journal-title":"Pediatrics"},{"key":"R29-18-20210202","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0022-3476(83)80278-9","article-title":"Seizures following childhood immunizations.","volume":"102","author":"Hirtz","year":"1983","journal-title":"J Pediatr"},{"key":"R30-18-20210202","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2012.08.057","article-title":"Measles, mumps, and rubella virus vaccine (M-M-R\u2122II): a review of 32 years of clinical and postmarketing experience.","volume":"30","author":"Lievano","year":"2012","journal-title":"Vaccine"},{"key":"R32-18-20210202","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0264-410X(99)00397-7","article-title":"Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella","volume":"18","author":"Tischer","year":"2000","journal-title":"Vaccine"},{"key":"R33-18-20210202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(97)00174-6","article-title":"Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines","volume":"16","author":"Schwarzer","year":"1998","journal-title":"Vaccine"},{"key":"R34-18-20210202","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF02962367","article-title":"Comparative study of reactogenicity and immunogenicity of new and established measles, mumps and rubella vaccines in healthy children.","volume":"26","author":"Usonis","year":"1998","journal-title":"Infection"},{"key":"R35-18-20210202","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/01.inf.0000183746.92218.f9","article-title":"Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.","volume":"24","author":"Feiterna-Sperling","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R36-18-20210202","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJM196007282630406","article-title":"Studies on an attenuated measles-virus vaccine. VI. Clinical, antigenic and prophylactic effects of vaccine in institutionalized children.","volume":"263","author":"Krugman","year":"1960","journal-title":"N Engl J Med"},{"key":"R37-18-20210202","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2105\/AJPH.52.Suppl_2.44","article-title":"Studies of live attenuated measles virus vaccine in man. II. Appraisal of efficacy.","volume":"52","author":"Hilleman","year":"1962","journal-title":"Am J Public Health Nations Health"},{"key":"R38-18-20210202","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJM196702022760502","article-title":"Live attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation.","volume":"276","author":"Hilleman","year":"1967","journal-title":"N Engl J Med"},{"key":"R39-18-20210202","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-3476(68)80334-8","article-title":"Field evaluation of live virus mumps vaccine.","volume":"72","author":"Sugg","year":"1968","journal-title":"J Pediatr"},{"key":"R40-18-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1542\/peds.44.2.217","article-title":"Protective efficacy of duck embryo rubella vaccines.","volume":"44","author":"Stokes","year":"1969","journal-title":"Pediatrics"},{"key":"R41-18-20210202","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMoa0706589","article-title":"Recent resurgence of mumps in the United States.","volume":"358","author":"Dayan","year":"2008","journal-title":"N Engl J Med"},{"key":"R42-18-20210202","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/529141","article-title":"Mumps vaccine performance among university students during a mumps outbreak.","volume":"46","author":"Cortese","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R43-18-20210202","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1086\/590115","article-title":"Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.","volume":"198","author":"Rubin","year":"2008","journal-title":"J Infect Dis"},{"key":"R44-18-20210202","first-page":"559","article-title":"Update: Multistate outbreak of mumps United States, January 1-May 2, 2006.","volume":"55","year":"2006","journal-title":"MMWR"},{"key":"R45-18-20210202","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.88.3.604","article-title":"Immunogenicity of subcutaneous versus intramuscular Oka\/Merck varicella vaccination in healthy children.","volume":"88","author":"Dennehy","year":"1991","journal-title":"Pediatrics"},{"key":"R46-18-20210202","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1741-7015-7-16","article-title":"Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.","volume":"7","author":"Gillet","year":"2009","journal-title":"BMC Med"},{"key":"R48-18-20210202","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1086\/317553","article-title":"Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: Intramuscular versus subcutaneous.","volume":"32","author":"Ruben","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000001241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:09:43Z","timestamp":1718600983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201609000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001241","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}